Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials (original) (raw)
Related papers
CNS Drugs, 2006
drome (PMS)/premenstrual dysphoric disorder (PMDD) have similar overall efficacy. While these treatments are more effective than placebo, response rates associated with them are far from satisfactory (<60%), such that, irrespective of treatment modality, there remain a significant number of women who are unresponsive to current conventional pharmacological therapy. The available data on response rates of specific types of premenstrual symptoms to, or symptom profiles that are most amenable to, each treatment modality are limited and not well defined because most studies were not designed to assess specific symptom profiles. Those studies that have attempted to evaluate which symptom profiles respond to specific therapies have revealed variations within the individual modalities, as well as between the different modalities. It appears that suppression of ovulation ameliorates a broad range of behavioural as well as
Premenstrual dysphoric disorder: a review for the treating practitioner
Cleveland Clinic journal of medicine, 2004
Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS), is characterized by physical and behavioral symptoms that cause marked social impairment during the last half of the menstrual cycle. Symptoms are believed to result from the interaction of central neurotransmitters and normal menstrual hormonal changes. Treatment usually begins with lifestyle changes, over-the-counter medications, and if needed, selective serotonin reuptake inhibitors. Physicians should be aware of the risks of many of the alternative therapies commonly touted in the popular press.
Selective Serotonin Reuptake Inhibitors for Premenstrual Dysphoric Disorder
Drugs, 2002
There have been a large number of studies conducted investigating the use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of patients with premenstrual dysphoric disorder (PMDD). The 12 randomised, controlled trials with continuous dose administration of SSRIs and the eight randomised, controlled trials with luteal phase dose administration (from ovulation to menses) are reviewed. All the treatment studies on fluoxetine, sertraline, paroxetine and citalopram have reported positive efficacy. Fluoxetine and sertraline have the largest literature, with a smaller number of studies endorsing paroxetine and citalopram. Mixed efficacy results have been reported with fluvoxamine. In general, adverse effects from the use of SSRIs in women with PMDD are the usual mild and transient adverse effects from SSRIs including anxiety, dizziness, insomnia, sedation, nausea and headache. Sexual dysfunction and weight gain can be problematic long-term adverse effects of SSRIs, but these effects have not been systematically evaluated with long-term SSRI use in women with PMDD. Serotonergic antidepressants have differential superiority over nonserotonergic antidepressants in the treatment of PMDD. Treatments that enhance
PREMENSTRUAL DYSPHORIC DISORDER - SELECTIVE SEROTONIN REUPPERATION INHIBITORS IN THE REGULATION OF SYMPTOMS AND THE POSITIVE EFFECTS OF PHARMACOTHERAPY ON THE QUALITY OF LIFE OF WOMEN WITH PMDD (Atena Editora), 2022
Premenstrual dysphoric disorder (PMDD) is a severe and disabling form of premenstrual syndrome that affects an average of 5% of women during their period. Studies show that the intense symptoms present during PMDD involve multiple factors, from genetic, ovarian or uterine, hormonal, neurological and psychological causes. These symptoms significantly impact the quality of life of women who suffer from this disorder, and serotonin inhibitors are considered the gold standard treatment for these cases, since they inhibit the release of hormones that stimulate the emergence of the aforementioned disorders. Therefore, the purpose of this chapter is to present the effectiveness of selective serotonin inhibitors (SSRIs) in the treatment of Premenstrual Dysphoric Disorder (PMDD). It is understood that studies have shown that SSRIs have reduced PMDD symptoms significantly. Likewise, each SSRI can cause particular adverse effects, which makes it necessary to choose the agent according to the characteristics of each patient.
Management Strategies for Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Annals of Pharmacotherapy, 2008
U p to 90% of women of childbearing age report experiencing premenstrual symptoms at some point in their lives. A smaller subset (up to 20%) report severe symptoms of premenstrual syndrome (PMS) that warrant treatment, and 3-8% are diagnosed as having a severe form known as premenstrual dysphoric disorder (PMDD). 1-3 This comprehensive review discusses the prevalence, etiology, symptomatology, and treatment of PMS/PMDD.
New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder
Archives of Women's Mental Health, 2002
Premenstrual dysphoric disorder was discussed by a panel of European researchers. The criteria for diagnosis of the condition, its categorisation as a mental disorder, and its differentiation from depression and premenstrual syndrome are all considered. Data on the treatment of premenstrual dysphoric disorder, using serotonin reuptake inhibitors and other therapies, are reviewed. An algorithm for the treatment of premenstrual dysphoric disorder is proposed.
The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD)
Psychoneuroendocrinology, 2003
Currently it is estimated that 3-8% of women of reproductive age meet strict criteria for premenstrual dysphoric disorder (PMDD). Assessment of published reports demonstrate that the prevalence of clinically relevant dysphoric premenstrual disorder is probably higher. 13-18% of women of reproductive age may have premenstrual dysphoric symptoms severe enough to induce impairment and distress, though the number of symptoms may not meet the arbitrary count of 5 symptoms on the PMDD list.